Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients
Authors
Keywords
-
Journal
ESMO Open
Volume 6, Issue 5, Pages 100231
Publisher
Elsevier BV
Online
2021-09-10
DOI
10.1016/j.esmoop.2021.100231
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ribociclib Population Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Analysis of Neutrophils in Cancer Patients
- (2021) Yasong Lu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
- (2020) Laura M Spring et al. LANCET
- Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis
- (2020) Alice Indini et al. Cancers
- Influence of Cow’s Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients
- (2020) G. D. Marijn Veerman et al. CLINICAL PHARMACOKINETICS
- Optimizing the Therapeutic Window of Targeted Drugs in Oncology: Potency‐guided First‐in‐Human Studies
- (2020) Matthew J Goldstein et al. CTS-Clinical and Translational Science
- Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
- (2020) C. Louwrens Braal et al. DRUGS
- The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer
- (2019) Manvi Sharma et al. CANCER
- Impact of Concomitant Administration of Gastric Acid–Suppressive Agents and Pazopanib on Outcomes in Soft-Tissue Sarcoma Patients Treated within the EORTC 62043/62072 Trials
- (2019) Olivier Mir et al. CLINICAL CANCER RESEARCH
- Concurrent proton-pump inhibitors increase risk of death for lung cancer patients receiving 1st-line gefitinib treatment - a nationwide population-based study
- (2019) Yu-Hung Fang et al. Cancer Management and Research
- 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†
- (2018) F Cardoso et al. ANNALS OF ONCOLOGY
- Effect of Concomitant pH‐Elevating Medications with Pazopanib on Progression‐Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma
- (2018) Renee K. McAlister et al. ONCOLOGIST
- Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer
- (2018) Grace G. Wong et al. Clinical Colorectal Cancer
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers
- (2017) Karthick Vishwanathan et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer
- (2017) Michael P. Chu et al. JAMA Oncology
- Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring EGFR Mutations
- (2016) Yoshitaka Zenke et al. Clinical Lung Cancer
- Effect of food and acid-reducing agents on the absorption of oral targeted therapies in solid tumors
- (2016) Annelieke E.C.A.B. Willemsen et al. DRUG DISCOVERY TODAY
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction
- (2016) Nesaretnam Barr Kumarakulasinghe et al. Oncotarget
- In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors
- (2015) Edouard Ollier et al. FUNDAMENTAL & CLINICAL PHARMACOLOGY
- P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib
- (2015) Mark C. de Gooijer et al. INVESTIGATIONAL NEW DRUGS
- Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors: An Update
- (2014) Ralph-Steven Wedemeyer et al. DRUG SAFETY
- Drug–drug interactions with tyrosine-kinase inhibitors: a clinical perspective
- (2014) Roelof W F van Leeuwen et al. LANCET ONCOLOGY
- Quantification of Gastrointestinal Liquid Volumes and Distribution Following a 240 mL Dose of Water in the Fasted State
- (2014) Deanna M. Mudie et al. MOLECULAR PHARMACEUTICS
- Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?
- (2014) Vincent H Ha et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib
- (2013) J.F. Hilton et al. LUNG CANCER
- Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug–Drug Interaction Potential for Molecular Targeted Agents in Clinical Development
- (2013) Gillian S. Smelick et al. MOLECULAR PHARMACEUTICS
- Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?
- (2012) N R Budha et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More